Drug profile · INN
fremanezumab-vfrm
AJOVY
fremanezumab-vfrm (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — fremanezumab-vfrm
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
fremanezumab-vfrm (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide antagonist
Primary target: Calcitonin gene-related peptide
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fremanezumab-vfrm?
fremanezumab-vfrm (AJOVY) is a calcitonin gene-related peptide antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for fremanezumab-vfrm?
AJOVY is a marketed brand name for fremanezumab-vfrm. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fremanezumab-vfrm?
fremanezumab-vfrm has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.